1)Kaliki S et al:Defining high-risk retinoblastoma:a multicenter global survey. JAMA Ophthalmol 140:30-36, 2022
2)Honavar SG et al:Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 120:923-931, 2002
3)Sastre X et al;International Retinoblastoma Staging Working Group:Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med 133:1199-1202, 2009
4)Kaliki S et al:Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 129:1422-1427, 2011
5)Chawla B et al:Multimodal therapy for stage Ⅲ retinoblastoma(International Retinoblastoma Staging System):a prospective comparative study. Ophthalmology 123:1933-1939, 2016
6)Aerts I et al:Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol 31:1458-1463, 2013
7)Skalet AH et al:Screening children at risk for retinoblastoma:consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology 125:453-458, 2018
8)Rushlow DE et al:Characterisation of retinoblastomas without RB1 mutations:genomic, gene expression, and clinical studies. Lancet Oncol 14:327-334, 2013
9)Kamihara J et al:Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res 23:e98-e106, 2017
10)Tonorezos ES et al:Recommendations for long-term follow-up of adults with heritable retinoblastoma. Ophthalmology 127:1549-1557, 2020
11)前田尚子・他:網膜芽細胞腫.JCCG長期フォローアップ委員会長期フォローアップガイドライン作成ワーキンググループ(編):小児がん治療後の長期フォローアップガイド.236-243,クリニコ出版,東京,2021